News & Articles

AstraZeneca BioPharmaceuticals R&D has invested in a LyoConstellationTM S10 freeze dryer intended to help drive research and development of small scale GMP production.

Study done at the University of Cambridge suggests a way to predict prognosis and most effective treatment in cancer

Roche's Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer

Women with a rare type of ovarian cancer could benefit from a drug that quadruples the likelihood of response compared with standard therapies

Cloud-based solution automates NGS data analysis for liquid biopsy and FFPE workflows

Tell us which new products made the most difference to your lab work and you’ll have the chance to win one of four $500 Amazon gift cards

Following last year’s success, we’re hosting our second annual event dedicated to celebrating our Seals of Quality program

Find out how one lab is streamlining the development of lentiviruses and transduction enhancers to treat a range of genetic diseases

Dr. John Connolly, CSO of Tessa Therapeutics, reveals how a new approach to cell-based therapy in cancer could circumvent severe immunotherapy side effects and effectively target aggressive solid tumors

Approval marks the second drug approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs and signals FDA’s continued focus on facilitating development of new treatments to fight antimicrobial resistant infections

The Atellica Solution from Siemens Healthineers promises more control and increased simplicity in your lab workflows

New partnership to advance Nosopharm’s lead candidate to clinical stage

Phase 1 trial scheduled for early 2020 will be first CAR-T cell therapy clinical trial to employ SMARTvector technology

Avacta’s first Affimer clinical candidate is a potent PD-L1 antagonist under development for solid tumor indications as the basis of bispecific and combination therapies

A small team of biotech scientists is targeting patient specific ‘neoantigens’ to improve response to adoptive T cell therapy in acute myeloid leukemia (AML)